Matthew H. Secrest

565 total citations · 1 hit paper
18 papers, 413 citations indexed

About

Matthew H. Secrest is a scholar working on Oncology, Pollution and Health, Toxicology and Mutagenesis. According to data from OpenAlex, Matthew H. Secrest has authored 18 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Pollution and 3 papers in Health, Toxicology and Mutagenesis. Recurrent topics in Matthew H. Secrest's work include Air Quality and Health Impacts (3 papers), Diabetes Treatment and Management (3 papers) and Energy and Environment Impacts (3 papers). Matthew H. Secrest is often cited by papers focused on Air Quality and Health Impacts (3 papers), Diabetes Treatment and Management (3 papers) and Energy and Environment Impacts (3 papers). Matthew H. Secrest collaborates with scholars based in United States, Canada and Switzerland. Matthew H. Secrest's co-authors include Kristian B. Filion, Jill Baumgartner, James J. Schauer, Ellison Carter, Xudong Yang, Pascal Reynier, Alexandra Lai, Bettina Habib, Mark J. Eisenberg and Jacob A. Udell and has published in prestigious journals such as Environmental Science & Technology, Blood and The Science of The Total Environment.

In The Last Decade

Matthew H. Secrest

18 papers receiving 408 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

2025 26 citations Richard Finn, Baek‐Yeol Ryoo et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Matthew H. Secrest

Since Specialization

Citations

This map shows the geographic impact of Matthew H. Secrest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew H. Secrest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew H. Secrest more than expected).

Fields of papers citing papers by Matthew H. Secrest

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew H. Secrest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew H. Secrest. The network helps show where Matthew H. Secrest may publish in the future.

Co-authorship network of co-authors of Matthew H. Secrest

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew H. Secrest. A scholar is included among the top collaborators of Matthew H. Secrest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew H. Secrest. Matthew H. Secrest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study breakdown → 2025 ·The Lancet Oncology ·Richard Finn, Baek‐Yeol Ryoo, (unknown), Daneng Li, Adam M. Burgoyne, (unknown), Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, (unknown), Sami Mahrus, Matthew H. Secrest, Colby S. Shemesh, Nancy Xiaonan Yu, Stephen P. Hack, Edward Cha, Edward Gane	26
2	EP07.04-26 Real-World Biomarker Testing and Treatment Patterns Identified Using Machine Learning in Early Non-small Cell Lung Cancer 2023 ·Journal of Thoracic Oncology ·(unknown), K. Schulze, (unknown), (unknown), Sarika Ogale, Ana Johnson, (unknown), Matthew H. Secrest, Aaron B. Cohen, Emily Castellanos, (unknown), Melissa Estévez, (unknown)	2
3	Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer 2022 ·The Oncologist ·(unknown), Cindy Yun, (unknown), Daniel Sheinson, (unknown), (unknown), Josina C. Reddy, Qing Zhang, Matthew H. Secrest, (unknown), Khaled Sarsour	8
4	Real-world treatment patterns and overall survival in BRAF -mutant melanoma patients treated with immunotherapy or targeted therapy 2022 ·Future Oncology ·Michael B. Atkins, Cristina Julián, Matthew H. Secrest, Janet Lee, (unknown), Edward McKenna	3
5	Factors associated with COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective cohort study using electronic health records from the USA 2021 ·BMJ Open ·Lisa Lindsay, Matthew H. Secrest, Shemra Rizzo, (unknown), Fei Yang, Larry Tsai	8
6	1574P Mortality of 1,636 COVID-19 cancer patients (pts) and associated prognostic factors 2021 ·Annals of Oncology ·Paolo A. Ascierto, Matthew H. Secrest, Peter Lambert, Khaled Sarsour, (unknown), (unknown), Jay P. Reddy, (unknown), (unknown), (unknown), Chang‐Ho Yun, (unknown)	1
7	Frequency of Early Refills for Opioids in the United States 2020 ·Pain Medicine ·David M. Kern, M. Soledad Cepeda, Maribel Salas, (unknown), Matthew H. Secrest, (unknown)	4
8	Prevalence of pyruvate kinase deficiency: A systematic literature review 2020 ·European Journal Of Haematology ·Matthew H. Secrest, (unknown), (unknown), Deborah Casso, (unknown), (unknown), Audra Boscoe	32
9	Prevalence of Red Cell Pyruvate Kinase Deficiency: A Systematic Literature Review 2019 ·Blood ·(unknown), Matthew H. Secrest, (unknown), (unknown), (unknown), Audra Boscoe, Deborah Casso	1
10	Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research 2019 ·Pharmacoepidemiology and Drug Safety ·Matthew H. Secrest, Robert W. Platt, Colin R. Dormuth, Dan Château, Laura E. Targownik, Rui Nie, Carla M. Doyle, Sophie Dell’Aniello, Kristian B. Filion	14
11	A population‐based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns 2019 ·Pharmacoepidemiology and Drug Safety ·Matthew H. Secrest, Laurent Azoulay, Matthew Dahl, Kristin K. Clemens, Madéleine Durand, Nianping Hu, Laura E. Targownik, Tanvir Chowdhury Turin, Colin R. Dormuth, Kristian B. Filion	11
12	Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real‐world example 2019 ·Pharmacoepidemiology and Drug Safety ·Matthew H. Secrest, Robert W. Platt, Pascal Reynier, Colin R. Dormuth, Andrea Benedetti, Kristian B. Filion	10
13	Identification of incident pancreatic cancer in Ontario administrative health data: A validation study 2018 ·Pharmacoepidemiology and Drug Safety ·Jennifer W. Wu, Laurent Azoulay, Anjie Huang, Michael J. Paterson, Fangyun Wu, Matthew H. Secrest, Kristian B. Filion	13
14	The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors 2017 ·Trends in Cardiovascular Medicine ·Matthew H. Secrest, Jacob A. Udell, Kristian B. Filion	31
15	Particulate matter chemical component concentrations and sources in settings of household solid fuel use 2017 ·Indoor Air ·Matthew H. Secrest, James J. Schauer, Ellison Carter, Jill Baumgartner	37
16	Carotid Stenting Versus Endarterectomy for Asymptomatic Carotid Artery Stenosis 2017 ·Stroke ·(unknown), Bettina Habib, Pascal Reynier, Matthew H. Secrest, Mark J. Eisenberg, Kristian B. Filion	71
17	The oxidative potential of PM2.5 exposures from indoor and outdoor sources in rural China 2016 ·The Science of The Total Environment ·Matthew H. Secrest, James J. Schauer, Ellison M. Carter, Alexandra Lai, Yuqin Wang, Ming Shan, Xudong Yang, Yuanxun Zhang, Jill Baumgartner	70
18	Seasonal and Diurnal Air Pollution from Residential Cooking and Space Heating in the Eastern Tibetan Plateau 2016 ·Environmental Science & Technology ·Ellison Carter, Scott Archer‐Nicholls, (unknown), Alexandra Lai, (unknown), Matthew H. Secrest, Sara Sauer, James J. Schauer, Majid Ezzati, Christine Wiedinmyer, Xudong Yang, Jill Baumgartner	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact